You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1913 Results
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
ODB - General Benefit
    fulvestrant
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative, Adjuvant
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
Funding:
Exceptional Access Program
    luspatercept - For the treatment of red-blood cell (RBC) transfusion-dependent anemia associated with Myelodysplastic Syndromes (MDS), according to clinical criteria
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Jun 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Stage IV Hodgkin Lymphoma
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
May 2023
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Oct 2024

Pages